Latest News On Drug Costs

Latest California Healthline Stories

KFF Health News' 'What the Health?': Dancing Under the Debt Ceiling

House Republicans passed their plan to raise the nation’s debt ceiling, along with major cuts to health (and other domestic) programs. Unlikely to become law, it calls for new work requirements for adults on Medicaid. Meanwhile, state efforts targeting trans people bear a striking resemblance to the fight against abortion rights. Jessie Hellmann of CQ Roll Call, Shefali Luthra of The 19th, and Sarah Karlin-Smith of the Pink Sheet join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Renuka Rayasam, who reported the latest KFF Health News-NPR “Bill of the Month” feature, about a specialist’s demand to be paid as much as $15,000 before treating a woman’s serious pregnancy complication.

KFF Health News' 'What the Health?': Will They or Won’t They (Block the Abortion Pill)?

The Supreme Court is considering the future of the abortion pill mifepristone, after GenBioPro sued the FDA over limitations that effectively block generic production of the drug, a major part of the market. Congress is considering proposals that would impose Medicaid work requirements, crack down on pharmacy benefit managers, and more. And President Joe Biden moved to expand health coverage to young immigrants known as “Dreamers.” Rachel Cohrs of Stat, Sandhya Raman of CQ Roll Call, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join KFF Health News’ Mary Agnes Carey to discuss these issues and more.

KFF Health News' 'What the Health?': The Confusing Fate of the Abortion Pill

The legality and availability of the abortion pill mifepristone is in question after a federal judge in Texas canceled the FDA’s approval of the first drug used in the two-drug medication abortion regimen. A 5th Circuit Court of Appeals panel overruled that decision in part, saying the pill should remain available, but only under the onerous restrictions in place before 2016. Meanwhile, another federal judge in Washington state issued a ruling in a separate case that conflicts with the Texas decision, ordering the FDA not to roll back any of its restrictions on the drug. Victoria Knight of Axios, Shefali Luthra of The 19th, and Sarah Karlin-Smith of the Pink Sheet join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and more.